How sevabertinib affects metformin levels in healthy adults
Treatments studied
This trial checks how a new cancer drug (sevabertinib) affects levels of a common diabetes medicine (metformin) in healthy adults. It helps doctors understand how to dose both drugs safely when used together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must be generally healthy, with no major health conditions like heart disease, diabetes, or cancer.
- You must be a non-smoker and have not used tobacco or nicotine in the last 6 months.
- You must not be pregnant or breastfeeding (if you are a woman).
- You must not be taking any regular medications or supplements (except vitamins).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This expanded access program provides sevabertinib, an investigational pill, to people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called a HER2 mutation and has stopped responding to previous treatments. The goal is to offer potential treatment when no other options are available.
This study tests if metformin, a common diabetes medicine, can help reduce insulin resistance in women who finished chemotherapy for early-stage breast cancer. It aims to improve long-term health and prevent future problems.
This trial tests how a new combination of drugs (BR3006A, BR3006B, and BR3006C) is absorbed and processed by the body when taken together, compared to a single tablet (BR3006). It is for healthy adults to understand the safety and behavior of the medication.
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.